Coronavirus
Conditions
Keywords
Plasma transfusion, Coronavirus
Brief summary
There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma.The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia.
Interventions
None listed
Sponsors
Shanghai Public Health Clinical Center
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* The participants were diagnosed as COVID-19; * Participants received anti-SARS-CoV-2 inactivated convalescent plasma * Written the informed consent.
Exclusion criteria
* Participants lacked detailed medical history
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1 | 1 day after receiving plasma transmission | The SARS-CoV-2 nuclei acid was quantified using RT-PCR |
| The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3 | 3 days after receiving plasma transmission | — |
| The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7 | 7 days after receiving plasma transmission | — |
| Numbers of participants with different Clinical outcomes | From receiving plasma transmission to 4 weeks | Clinical outcomes include death, critical illness, recovery |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | 4 weeks after receiving plasma transmission |
Countries
China
Contacts
Primary ContactHongzhou Lu, Ph.D
Outcome results
None listed